{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:59:01Z","timestamp":1768010341313,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T00:00:00Z","timestamp":1469059200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["2G12MD007592"],"award-info":[{"award-number":["2G12MD007592"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lizanell and Colbert Coldwell Foundation"},{"name":"Margaret G. Marsh Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s13277-016-5179-7","type":"journal-article","created":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T03:00:30Z","timestamp":1469070030000},"page":"12643-12654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment"],"prefix":"10.1007","volume":"37","author":[{"given":"Derrick M.","family":"Oaxaca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Ah","family":"Yang-Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgialina","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan G.","family":"Staniswalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Kirken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,21]]},"reference":[{"key":"5179_CR1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243:290\u20133.","journal-title":"Nature"},{"key":"5179_CR2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447\u201359.","journal-title":"Lancet"},{"key":"5179_CR3","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","volume":"6","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of bcr-abl inhibitors. Nat Rev Drug Discov. 2007;6:834\u201348.","journal-title":"Nat Rev Drug Discov"},{"key":"5179_CR4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, M\u00fcller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R. Safety and efficacy of imatinib in cml over a period of 10\u00a0years: data from the randomized cml-study iv. Leukemia. 2015;29:1123\u201332.","journal-title":"Leukemia"},{"key":"5179_CR5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF, Part i. Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8:1018\u201329.","journal-title":"Lancet Oncol"},{"key":"5179_CR6","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brummendorf TH. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012;119:3403\u201312.","journal-title":"Blood"},{"key":"5179_CR7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf 3rd CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T. Ap24534, a pan-bcr-abl inhibitor for chronic myeloid leukemia, potently inhibits the t315i mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401\u201312.","journal-title":"Cancer Cell"},{"key":"5179_CR8","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MWN, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075\u201388.","journal-title":"N Engl J Med"},{"key":"5179_CR9","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.18632\/oncotarget.692","volume":"3","author":"O Cassuto","year":"2012","unstructured":"Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib. Oncotarget. 2012;3:1557\u201365.","journal-title":"Oncotarget"},{"key":"5179_CR10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernandez-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T. Bcr-abl1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in ph chromosome-positive leukemia. Cancer Cell. 2014;26:428\u201342.","journal-title":"Cancer Cell"},{"key":"5179_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nbt0114-9a","volume":"32","author":"M Senior","year":"2014","unstructured":"Senior M. Fda halts then allows sales of ariad's leukemia medication. Nat Biotechnol. 2014;32:9\u201311.","journal-title":"Nat Biotechnol"},{"key":"5179_CR12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2014","unstructured":"Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in cml patients treated with bcr\/abl1 kinase inhibitors. Blood. 2014;125:901\u20136.","journal-title":"Blood"},{"key":"5179_CR13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/stem.5530010205","volume":"1","author":"I Kubonishi","year":"1983","unstructured":"Kubonishi I, Miyoshi I. Establishment of a ph 1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning. 1983;1:105\u201317.","journal-title":"Int J Cell Cloning"},{"key":"5179_CR14","doi-asserted-by":"crossref","unstructured":"Rosenhahn J, Weise A, Michel S, Hennig K, Hartmann I, Schiefner J, Schubert K, Liehr T, Von Eggeling F, Loncarevic I. Cytogenetic characterisation and proteomic profiling of the imatinib-resistant cell line kcl22-r. Int J Oncol 2007.","DOI":"10.3892\/ijo.31.1.121"},{"key":"5179_CR15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2353\/jmoldx.2008.070128","volume":"10","author":"J Laudadio","year":"2008","unstructured":"Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD. An intron-derived insertion\/truncation mutation in the bcr-abl kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn. 2008;10:177\u201380.","journal-title":"J Mol Diagn"},{"key":"5179_CR16","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1535-7163.MCT-08-0482","volume":"7","author":"TS Lee","year":"2008","unstructured":"Lee TS, Ma W, Zhang X, Giles F, Cortes J, Kantarjian H, Albitar M. Bcr-abl alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008;7:3834\u201341.","journal-title":"Mol Cancer Ther"},{"key":"5179_CR17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","volume":"22","author":"B Peng","year":"2004","unstructured":"Peng B. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935\u201342.","journal-title":"J Clin Oncol"},{"key":"5179_CR18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2009.09.006","volume":"290","author":"Z Lu","year":"2010","unstructured":"Lu Z, Jin Y, Qiu L, Lai Y, Pan J. Celastrol, a novel hsp90 inhibitor, depletes bcr\u2013abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring t315i mutation. Cancer Lett. 2010;290:182\u201391.","journal-title":"Cancer Lett"},{"key":"5179_CR19","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/annonc\/mdg316","volume":"14","author":"MP Goetz","year":"2003","unstructured":"Goetz MP. The hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol. 2003;14:1169\u201376.","journal-title":"Ann Oncol"},{"key":"5179_CR20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jep.2012.09.005","volume":"144","author":"J Zhang","year":"2012","unstructured":"Zhang J, Li C-Y, Xu M-j, Wu T, Chu J-H, Liu S-J, Ju W-Z. Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats. J Ethnopharmacol. 2012;144:195\u2013200.","journal-title":"J Ethnopharmacol"},{"key":"5179_CR21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-2007-969566","volume":"51","author":"H Ammon","year":"1985","unstructured":"Ammon H, M\u00fcller A. Forskolin: from an ayurvedic remedy to a modern agent. Planta Med. 1985;51:473\u20137.","journal-title":"Planta Med"},{"key":"5179_CR22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D. The tumor suppressor pp2a is functionally inactivated in blast crisis cml through the inhibitory activity of the bcr\/abl-regulated set protein. Cancer Cell. 2005;8:355\u201368.","journal-title":"Cancer Cell"},{"key":"5179_CR23","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","volume":"98","author":"FE Nicolini","year":"2013","unstructured":"Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Muller MC, Hochhaus A, Dufva IH, Kim DW, Cortes J, Mauro MJ, Chuah C, Labussiere H, Morisset S, Roche-Lestienne C, Lippert E, Hayette S, Peter S, Zhou W, Maguer-Satta V, Michallet M, Goldman J, Apperley JF, Mahon FX, Marin D, Etienne G. The bcr-ablt315i mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98:1510\u20136.","journal-title":"Haematologica"},{"key":"5179_CR24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/toxsci\/kfu215","volume":"143","author":"DR Talbert","year":"2014","unstructured":"Talbert DR, Doherty KR, Trusk PB, Moran DM, Shell SA, Bacus S. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. Toxicol Sci. 2014;143:147\u201355.","journal-title":"Toxicol Sci"},{"key":"5179_CR25","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"18","author":"D Cilloni","year":"2011","unstructured":"Cilloni D, Saglio G. Molecular pathways: Bcr-abl. Clin Cancer Res. 2011;18:930\u20137.","journal-title":"Clin Cancer Res"},{"key":"5179_CR26","first-page":"278","volume":"4","author":"C Kavitha","year":"2010","unstructured":"Kavitha C, Rajamani K, Vadivel E. Coleus forskohlii: a comprehensive review on morphology, phytochemistry and pharmacological aspects. J Med Plants Res. 2010;4:278\u201385.","journal-title":"J Med Plants Res"},{"key":"5179_CR27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/147323001003800229","volume":"38","author":"M Huerta","year":"2010","unstructured":"Huerta M, Urzua Z, Trujillo X, Gonzalez-Sanchez R, Trujillo-Hernandez B. Forskolin compared with beclomethasone for prevention of asthma attacks: a single-blind clinical trial. J Int Med Res. 2010;38:661\u20138.","journal-title":"J Int Med Res"},{"key":"5179_CR28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cncr.22816","volume":"110","author":"DT Milton","year":"2007","unstructured":"Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer. 2007;110:599\u2013605.","journal-title":"Cancer"},{"key":"5179_CR29","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR. Phase i dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009;15:6232\u201340.","journal-title":"Clin Cancer Res"},{"key":"5179_CR30","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329\u201338.","journal-title":"Lancet"},{"key":"5179_CR31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0093-7754(03)70012-8","volume":"30","author":"M Hidalgo","year":"2003","unstructured":"Hidalgo M, Bloedow D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (tarceva). Semin Oncol. 2003;30:25\u201333.","journal-title":"Semin Oncol"},{"key":"5179_CR32","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1158\/1078-0432.CCR-07-4417","volume":"14","author":"QS Chu","year":"2008","unstructured":"Chu QS, Cianfrocca ME, Goldstein LJ, Gale M, Murray N, Loftiss J, Arya N, Koch KM, Pandite L, Fleming RA, Paul E, Rowinsky EK. A phase i and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res. 2008;14:4484\u201390.","journal-title":"Clin Cancer Res"},{"key":"5179_CR33","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","volume":"30","author":"DL Deremer","year":"2008","unstructured":"Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008;30:1956\u201375.","journal-title":"Clin Ther"},{"key":"5179_CR34","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Phase i clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor bay 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965\u201372.","journal-title":"J Clin Oncol"},{"key":"5179_CR35","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","volume":"13","author":"JR Infante","year":"2012","unstructured":"Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris Jr HA, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral mek inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:773\u201381.","journal-title":"Lancet Oncol"},{"key":"5179_CR36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00280-013-2324-5","volume":"73","author":"JF Grippo","year":"2014","unstructured":"Grippo JF, Zhang W, Heinzmann D, Yang KH, Wong J, Joe AK, Munster P, Sarapa N, Daud A. A phase i, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with braf v600e mutation-positive metastatic melanoma. Cancer Chemother Pharmacol. 2014;73:103\u201311.","journal-title":"Cancer Chemother Pharmacol"},{"key":"5179_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-62703-242-1_1","volume":"967","author":"JA Ross","year":"2013","unstructured":"Ross JA, Rodriguez G, Kirken RA. Analysis of janus tyrosine kinase phosphorylation and activation. Methods Mol Biol. 2013;967:3\u201320.","journal-title":"Methods Mol Biol"},{"key":"5179_CR38","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621\u201381.","journal-title":"Pharmacol Rev"},{"key":"5179_CR39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1198\/sbr.2009.0001","volume":"1","author":"JJ Lee","year":"2009","unstructured":"Lee JJ, Kong M. Confidence intervals of interaction index for assessing multiple drug interaction. Stat Biopharm Res. 2009;1:4\u201317.","journal-title":"Stat Biopharm Res"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-5179-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-016-5179-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-5179-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:52:56Z","timestamp":1498315976000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-016-5179-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,21]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["5179"],"URL":"https:\/\/doi.org\/10.1007\/s13277-016-5179-7","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,21]]}}}